Sorafenib (D06272) is a multi-kinase inhibitor by targeting Raf/MEK/ER pathway, and approved for the treatment of advanced renal cell carcinoma and advanced hepatocellular carcinoma [77]. The gene discussed is MAP2K7; the disease is hereditary clear cell renal cell carcinoma.